Acumen Pharmaceuticals (ABOS) Cash from Investing Activities (2021 - 2026)

Acumen Pharmaceuticals has reported Cash from Investing Activities for 6 years, with the latest figure at -$13.8 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 148.13% year-over-year to -$13.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.4 million (up 6.42% YoY) and the FY2025 annual result came in at $133.9 million, up 178.87% from the prior year.
• Cash from Investing Activities declined to -$13.8 million in Q1 2026 per ABOS's latest filing, from $26.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $55.9 million in Q3 2022 and troughed at -$92.0 million in Q3 2023.
• A 5-year average of $2.1 million and a median of $8.8 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities slumped 722.26% in 2023, then soared 499.83% in 2025.
• Over 5 years, Cash from Investing Activities stood at -$20.4 million in 2022, then slumped by 139.02% to -$48.8 million in 2023, then surged by 160.78% to $29.7 million in 2024, then fell by 11.51% to $26.2 million in 2025, then sank by 152.6% to -$13.8 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$13.8 million, $26.2 million, and $40.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.